Alnylam’s Patisiran Shows Promise for Treating FAP in Phase 2 Trial
Patisiran (ALN-TTR02) led to an improvement in average nerve dysfunction in 26 patients with familial amyloid polyneuropathy (FAP), a rare disease that causes organ or nerve malfunction. Moreover, all 25 eligible participants in the Phase 2 open label extension (OLE) study of patisiran were enrolled in the Phase 3 APOLLO…